Compounds for the treatment of sexual dysfunction
CA 2415557 A1 · Owner: Pfizer Inc. · Inventors: Wayman, Christopher Peter; Harrow, Ian Dennis; Phillips, Stephen Charles
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Polynucleotide sequences encoding a novel human soluble secreted endopeptidase (SEP) at SEQ ID NO:2 are described and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO:1 or SEQ ID NO: 5 and variants fragments, homologues, analogues and , derivatives thereof (b) a polypeptide of SEQ ID NO: 2 and variants fragments, homologues, analogues and derivatives thereof; (c) a polypeptide encoded by the cDAN Ana NCIMB 41110 and variants fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which at least 78 % identify to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 16, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 16, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 16, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.